GSK vs. WBA

Last updated Apr 2, 2026

Compare and contrast key facts about GlaxoSmithKline plc (GSK) and Walgreens Boots Alliance, Inc. (WBA).

Performance

GSK vs. WBA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in GlaxoSmithKline plc (GSK) and Walgreens Boots Alliance, Inc. (WBA). The values are adjusted to include any dividend payments, if applicable.

GSK vs. WBA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
GSK GlaxoSmithKline plc	15.09%	51.23%	-5.14%	9.71%	-33.41%	26.74%	-17.72%	29.24%	13.79%	-2.97%
WBA Walgreens Boots Alliance, Inc.	0.00%	28.40%	-61.34%	-25.09%	-25.06%	35.78%	-29.38%	-10.99%	-3.65%	-10.51%

Fundamentals

EPS GSK : $2.78 WBA : -$7.28
PS Ratio GSK : 3.59 WBA : 0.07
Total Revenue (TTM) GSK : $31.95B WBA : $154.58B
Gross Profit (TTM) GSK : $23.18B WBA : $26.47B
EBITDA (TTM) GSK : $11.62B WBA : -$2.92B

Returns By Period

GSK

• 1D: 1.45%
• 1M: -3.95%
• YTD: 15.09%
• 6M: 25.10%
• 1Y: 53.75%
• 3Y*: 21.01%
• 5Y*: 9.06%
• 10Y*: 5.89%

WBA

• 1D: —
• 1M: —
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

GSK vs. WBA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

GSK

GSK Risk / Return Rank: 86
GSK Sharpe Ratio Rank: 89
GSK Sortino Ratio Rank: 86
GSK Omega Ratio Rank: 83
GSK Calmar Ratio Rank: 87
GSK Martin Ratio Rank: 84

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

GSK vs. WBA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for GlaxoSmithKline plc (GSK) and Walgreens Boots Alliance, Inc. (WBA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	GSK	WBA	Difference
Sharpe ratio Return per unit of total volatility	1.91	—	—
Sortino ratio Return per unit of downside risk	2.51	—	—
Omega ratio Gain probability vs. loss probability	1.32	—	—
Calmar ratio Return relative to maximum drawdown	3.40	—	—
Martin ratio Return relative to average drawdown	7.88	—	—
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

Sharpe Ratios by Period

	GSK	WBA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.91	—	—
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.37	—	—
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.26	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.33	—	—

Correlation

The correlation between GSK and WBA is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

GSK vs. WBA - Dividend Comparison

GSK's dividend yield for the trailing twelve months is around 3.14%, while WBA has not paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
GSK GlaxoSmithKline plc	3.14%	3.42%	4.60%	3.75%	5.47%	4.99%	5.59%	4.35%	5.65%	5.83%	6.86%	5.93%
WBA Walgreens Boots Alliance, Inc.	0.00%	0.00%	10.72%	7.35%	5.13%	3.62%	4.64%	3.04%	2.46%	2.13%	1.78%	1.64%

Drawdowns

Drawdown Indicators

	GSK	WBA	Difference
Max Drawdown Largest peak-to-trough decline	-55.70%	—	—
Max Drawdown (1Y) Largest decline over 1 year	-14.80%	—	—
Max Drawdown (5Y) Largest decline over 5 years	-50.10%	—	—
Max Drawdown (10Y) Largest decline over 10 years	-50.10%	—	—
Current Drawdown Current decline from peak	-7.75%	—	—
Average Drawdown Average peak-to-trough decline	-18.90%	—	—
Ulcer Index Depth and duration of drawdowns from previous peaks	6.38%	—	—

Volatility

Volatility by Period

	GSK	WBA	Difference
Volatility (1M) Calculated over the trailing 1-month period	7.17%	—	—
Volatility (6M) Calculated over the trailing 6-month period	19.19%	—	—
Volatility (1Y) Calculated over the trailing 1-year period	28.45%	—	—
Volatility (5Y) Calculated over the trailing 5-year period, annualized	24.75%	—	—
Volatility (10Y) Calculated over the trailing 10-year period, annualized	22.72%	—	—

Financials